Sanderporter1074

It remains challenging for pure-phase catalysts to achieve high performance during the electrochemical oxygen reduction reaction to overcome the sluggish kinetics without the assistance of extrinsic conditions. Herein, a series of pristine perovskites, i.e., AMnO3 (A = Ca, Sr, and Ba), are proposed with various octahedron stacking configurations to demonstrate the cooperative catalysis over SrMnO3 jointly explored by experiments and first-principles calculations. #link# Comparing with the unitary stacking of coordination units in CaMnO3 or BaMnO3 , the intrinsic SrMnO3 with a mixture of corner-sharing and face-sharing octahedron stacking configurations demonstrates superior activity (Ehalf-wave = 0.81 V), and charge-discharge stability over 400 h without the voltage gap (≈0.8 V) increasing in zinc-air batteries. The theoretical study reveals that, on the SrMnO3 (110) surface, the active sites switch from coordinatively unsaturated atop Mn (*OO, *OOH) to Mn-Mn bridge (*O, *OH). Therefore, the intrinsic dual coordination environments of Mn-Ocorner and Mn-Oface enable cooperative modulation of the interaction strength of the oxygen intermediates with the surface, inducing the decrease of the *OH desorption energy (rate-limiting step) unrestricted by scaling relationships with the overpotential of ≈0.28 V. This finding provides insights into catalyst design through screening intrinsic structures with multiple coordination unit stacking configurations.Rosacea is a common skin disease that is troublesome for both the patients and the dermatologists. Erythema, telangiectasia, papulopustular changes, and phymatous changes are the main problems faced by the patients and dermatologists in everyday practice. Due to the chronic and relapsing nature of the disease, patients are usually unsatisfied with conventional treatment methods. Akti-1/2 in vitro report a case of a patient with rosacea, erythematotelangiectatic subtype with an eight-year history of progressive worsening and experience of combined therapy based on the broadband pulse light and topical 0.5% brimonidine tartrate gel. The effectiveness of the therapy was evaluated using multispectral skin imaging that enables to define morphological patterns of the pathological skin areas in a real-time mode as well as to create the map of hemoglobin distribution and to measure its concentration in the rosacea foci. In this case report, an efficacy and very good tolerability of the abovementioned treatment have been demonstrated.Human skin is equipped with slow adapting (SA) and fast adapting (FA) capabilities simultaneously. To mimic such functionalities, elaborately designed devices have been explored by integrating multiple sensing elements or adopting multimode sensing principles. However, the complicated fabrication, signal mismatch of different modules, complex operation, and high power-consumption hinder their widespread applications. Here, a new type of single-mode and self-powered mechanoreceptor that can mimic both SA and FA via seamless fusion of complementary while compatible potentiometric and triboelectric sensing principles is reported. The resultant potentiometric-triboelectric hybridized mechanoreceptor exhibits distinctive features that are hard to achieve via currently existing methods, including single-mode output (only voltage signal), greatly simplified operation (single-measurement setup), ultralow power-consumption ( less then 1 nW), self-adaptive response behavior, and good capability for resolving complex stimuli. Diverse mechanical characteristics, including magnitude, duration, frequency, applying and releasing speed, can be well interpreted with this single-mode and self-powered mechanoreceptor. Its promising application for monitoring object manipulations with a soft robotic gripper is explored. Furthermore, the versatility of the mechanoreceptor for resolving complex stimuli in diverse daily scenarios is demonstrated. This work presents a new design that will significantly simplify the fabrication/operation and meanwhile boost the functionality/energy-efficiency of future electronic devices and smart systems.Periprosthetic joint infection (PJI) is a rare postoperative complication that is treated with antibiotic spacers. Some patients develop severe, treatment-resistant, chronic PJI despite multiple attempts at salvaging the joint. Permanent resection of the joint or amputation may be the only definitive treatment. The purpose of this study is to describe the outcomes, infection resolution rate, and complications of two-stage revision, utilizing extensive resection of the affected bone and application of antibiotic megaspacers as a modality for limb-salvage. A review of 12 patients, initially referred for amputation due to chronically failed PJI, was conducted. All patients underwent extensive resection of the bone and surgical implantation of a custom-made antibiotic megaspacer between December 2016 and June 2019. Thirteen megaspacers were placed in 13 infected joints in 12 patients with a history of chronic PJI. Six patients (50%) had a diagnosis of osteomyelitis. Eradication of the infection leading to limb-salvage was successful in nine patients. Visual Analog Scale pain scores improved by 3.5, or 50%, after two-stage revision with megaprosthesis reimplantation (p = .008), and six patients (54.5%) had improvement in ambulation. Complication rates, not including reinfection or recurrence, following megaspacer and megaprosthesis reimplantation were 58.3% and 27.3%, respectively. One patient underwent amputation due to a life-threatening infection while two other patients underwent amputation due to debilitating complications following limb-salvage surgery. Statement of Clinical Significance In patients whose PJI becomes treatment-resistant after multiple failed attempts at traditional two-stage exchange, performing extensive boney resection with placement of an antibiotic-laden megaspacer can be an effective method of achieving limb-salvage.

Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal.

To evaluate the effect of fremanezumab on the rate of reversion from CM to EM.

This phase 3, randomized, double-blind, placebo-controlled, parallel-group trial included a 28-day pretreatment period and a 3-month treatment period. Patients with CM received subcutaneous fremanezumab quarterly (675mg at baseline) or monthly (675mg at baseline; 225mg at Weeks 4 and 8), or placebo. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as either a reduction to an average of <15 headache days per month during the 3-month treatment period or a reduction to <15 headache days per month in all 3months of the treatment period.

This analysis included data from 1088 CM patients (quarterly, n=366; monthly, n=365; placebo, n=357). More fremanezumab-treated patients with CM reverted to EM using either the monthly average number of headache days criteria for reversion (quarterly 50.